DREAMM-8
DREAMM-8 is the second confirmatory win for belantamab, in lenalidomide-exposed patients.
12-month PFS 71% vs 51% (HR 0.52); OS trend favourable. Supported 2025 US approval with pomalidomide-dexamethasone.
Setting
Relapsed myeloma after ≥1 line including lenalidomide: belantamab-Pd vs Pom-Vd
Phase
Phase 3
Sponsor
GSK
Registry
Headline result
PFS HR 0.52.
Reported
2024
Enrolled
302
In plain words
What these results mean for people, not percentages
Progression-free survival at 12 monthsprimarysurrogate endpoint
- 71 vs 51 out of 100 alive without the cancer growing at 12 months with Belantamab-Pd compared with Pom-Vd; 20 more per 100.
- Roughly one extra person helped for every 5 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 48 percent lower chance of the event at any given time (hazard ratio 0.52, likely range 0.37 to 0.73).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Relapsed myeloma after ≥1 line including lenalidomide: belantamab-Pd vs Pom-Vd. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.